跳到主要內容

臺灣博碩士論文加值系統

(18.97.14.86) 您好!臺灣時間:2025/02/12 11:38
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:陳博玄
研究生(外文):Po-Hsuan
論文名稱:Tongkat Ali (Eurycoma longifolia)降低PDE5A基因表現及增加血漿中NO和cGMP濃度的探討
論文名稱(外文):Tongkat Ali (Eurycoma longifolia) decrease the PDE5A gene expression and enhance the NO and cGMP concentration of the plasma.
指導教授:徐成金徐成金引用關係
學位類別:碩士
校院名稱:中山醫學大學
系所名稱:醫學研究所
學門:醫藥衛生學門
學類:醫學學類
論文種類:學術論文
論文出版年:2009
畢業學年度:97
語文別:中文
論文頁數:73
相關次數:
  • 被引用被引用:3
  • 點閱點閱:1433
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
Tongkat Ali (Eurycoma longifolia)為苦木科(Simaroubaceae) Eurycoma屬之植物,主要分布於東南亞地區,如印尼、馬來半島、泰國、越南等地。此植物在馬來西亞當地被廣泛的應用在藥用及食用中,主要有消除疲勞、恢復體力、抗氧化、增強性功能、促血液循環、治療皮膚病、糖尿病、潰瘍等功能,於東南亞各地被視為萬應仙丹,此外此植物更有“馬來西亞人蔘”之稱;由此可知此植物的重要性。於馬來西亞當地研究曾指出E.longifolia的根部萃取物,具有抗高血壓、抗痢疾、減輕疲勞、促進食慾和消化能力、調節膚質和肌肉、增強免疫力等功效。
本研究目的是在探討小鼠餵食Tongkat Ali (Eurycoma longifolia)後對於體內一氧化氮和環狀單磷酸鳥糞嘌呤濃度之影響,是否與sildenafil 抑制第五型磷酸二脂解酶作用途徑相似,並評估其安全性。飼料添加人體服用劑量的Tongkat Ali、sildenafil、arginine、Tongkat Ali plus ginseng、山藥五種飼料餵食雄性Balb/c小鼠,並在兩週、四週斷頸犧牲,採取血液、肝臟、腎臟、海綿體進行分析。研究結果顯示,兩週、四週小鼠血漿中一氧化氮及環狀單磷酸鳥糞嘌呤濃度各組皆有增加,並降低海綿體中第五型磷酸二脂解酶mRNA表現,至於相關藥物代謝酵素CYP3A11之mRNA變化,又以四週Tongkat Ali處理組及Tongkat Ali plus ginseng組有顯著激活表現;另外在肝臟及腎臟脂質過氧化分析中,處理組和對照組無顯著差異,臟器麩胱苷肽(GSH)相關酵素活性也無顯著激活情形。
因此本實驗證實,Tongkat Ali可透過降低第五型磷酸二脂解酶活性,增加血漿中一氧化氮及環狀單磷酸鳥糞嘌呤濃度,此外並不會造成肝、腎臟器的傷害。


Eurycoma longifolia (Tongkat Ali) is a plant with folk medicine in Indonesia, Malaysia, Thailand and Vietnam. The residences in Malaysia usually treat it as “ginseng of Malaysia”, and think it possesses multiple medical functions such as anti-hypertension and appetite stimulation.
The purpose of this project was to examine the effect of E. longifolia extract on plasma NO and cGMP concentration in mice. Viagra was also used for comparison. Mice were treated by E. longifolia, Viagra, L-Arginine, Tongkat Ali plus ginseng, Dioscorea for 2 and 4 weeks. Plasma NO, cGMP level and the activity of type 5 phophodiesterase and cytochrome P450 were analyzed.
Results showed that 5 treatments increased the NO and cGMP levels, and inhibited the activity of type 5 phophodiesterase. Tongkat Ali and Tongkat Ali plus ginseng treated mice at 4 weeks has significantly higher cytochrome P450 mRNA expression. These treatments did not affect the anti-oxidative defense in liver and kidney.
These findings implied that Tongkat Ali could provide protective or medical functions via elevating plasma NO and cGMP concentration and decreasing PDE5 enzyme activity.


目次
目次……………………………………………………………………Ⅰ
中文摘要………………………………………………………………Ⅴ
英文摘要………………………………………………………………Ⅶ
第一章 、前言………………………………………………………1
第二章 、文獻探討…………………………………………………3
一、 東哥阿里(Tongkat Ali)………………………………… 3
二、 人蔘…………………………………………………………4
三、 山藥…………………………………………………………6
四、 心血管系統…………………………………………………8
五、 一氧化氮(NO)………………………………………………10
六、 第五型磷酸二脂解酶………………………………………12
七、 細胞色素P450………………………………………………14
八、 丙二醛………………………………………………………16
九、 抗氧化系統…………………………………………………18
十、 麩胱苷肽……………………………………………………19
十一、 麩胱苷肽過氧化酶…………………………………………19
第三章 、研究目的…………………………………………………21
第四章 、實驗材料與方法…………………………………………22
一、 實驗材料……………………………………………………22
(一)、實驗動物……………………………………………………22
(二)、化學試藥……………………………………………………22
(三)、設備儀器……………………………………………………25
二、實驗方法…………………………………………………………26
(一)、實驗動物、設計……………………………………………26
(二)、實驗原料及飼料配置………………………………………27
(三)、血液和臟器之收集…………………………………………28
三、實驗分析…………………………………………………………29
(一)、一氧化氮(NO)測定………………………………………29
(二)、環狀單磷酸鳥糞嘌呤(cGMP)測定………………………30
(三)、總蛋白質濃度之測定……………………………………31
(四)、脂質過氧化之丙二醛(Malondialdehyde)濃度測定…32
(五)、麩胱苷肽(Glutathione;GSH)濃度測定………………33
(六)、麩胱苷肽過氧化酶(Glutathione Peroxidase) 活性測定34
(七)、海綿體、小腸mRNA測量…………………………………36
四、統計分析……………………………………………………39
第五章 、實驗結果…………………………………………………40
第六章 、討論………………………………………………………45
第七章 、結論………………………………………………………52
第八章 、文獻參考…………………………………………………62
圖表目次
表一、小鼠之體重變化情形……………………………………………53
圖一、Viagra調控平滑肌張力途徑……………………………………13
圖二、GSH、GSSG氧化還原反應………………………………………20
圖三、 NO測定方法……………………………………………………29
圖四、血漿中NO濃度表現………………………………………………54
圖五、血漿中cGMP濃度表現……………………………………………55
圖六、小鼠海綿體PDE5A mRNA 表現…………………………………56
圖七、小鼠小腸中CYP3A11 mRNA 表現………………………………57
圖八、肝臟MDA表現……………………………………………………58
圖九、腎臟MDA表現……………………………………………………59
圖十、肝臟中GSH表現…………………………………………………60
圖十一、肝臟中GPx表現………………………………………………61


文獻參考
1.Ang HH, Cheang HS, Yusof AP: Effects of Eurycoma longifolia Jack (Tongkat Ali) on the initiation of sexual performance of inexperienced castrated male rats. Experimental Animals 2000;49:35-38.
2.甘偉松: 藥用植物學 第七版. 台北, 中國醫藥研究所出版, 1986.
3.Hideji I, Koichi T, Yukio H, HiroshiI M: Antitumor compounds isolated from higher plants. Journal of the Pharmaceutical Society of Japan 2000;4:213-222.
4.Chan KL, Lee SP, Yuen KH: Chemical Prospecting in Malayan Forest; In Antipyretic activity of quassinoids from Eurycoma longifolia Jack. Selangor, 1995.
5.Chan KL, O''Neill M J, Phillipson JD, Warhurst DC: Plants as Sources of Antimalarial Drugs. Part 31 Eurycoma longifolia. Planta Medica 1986;52:105-107.
6.Morita H, Kishi E, Takeya K, Itokawa H, Tanaka O: New Quassinoids from the Roots of Eurycoma longifolia. Chemistry Letters 1990;19:749-752.
7.Ang HH, Sim MK: Eurycoma longifolia Jack enhances libido in sexually experienced male rats. Experimental Animals 1997;46:287-290.
8.Ang HH, Sim MK: Eurycoma longifolia JACK and orientation activities in sexually experienced male rats. Biological & pharmaceutical bulletin 1998;21:153-155.
9.Adimoelja A: Phytochemicals and the breakthrough of traditional herbs in the management of sexual dysfunctions. International journal of andrology 2000;23 Suppl 2:82-84.
10.Lin L-C, Peng C-Y, Wang H-S, Lee K-W, Wang PS: Reinvestigation of the Chemical Constituents of Eurycoma longifolia. The Chinese Pharmaceutical Journal 2001;53:97-106.
11.Kass DA, Champion HC, Beavo JA: Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circulation Research 2007;101:1084-1095.
12.Hong B, Ji YH, Hong JH, Nam KY, Ahn TY: A double-blind crossover study evaluating the efficacy of korean red ginseng in patients with erectile dysfunction: a preliminary report. The Journal of Urology 2002;168:2070-2073.
13.Suh SO, Kroh M, Kim NR, Joh YG, Cho MY: Effects of red ginseng upon postoperative immunity and survival in patients with stage III gastric cancer. The American Journal of Chinese Medicine 2002;30:483-494.
14.Yun TK, Lee YS, Lee YH, Kim SI, Yun HY: Anticarcinogenic effect of Panax ginseng C.A. Meyer and identification of active compounds. The Korean Academy of Medical Sciences 2001;16 Suppl:S6-18.
15.Deng HL, Zhang JT: Anti-lipid peroxilative effect of ginsenoside Rb1 and Rg1. Chinese Medical Journal 1991;104:395-398.
16.Yu SC, Li XY: Effect of ginsenoside on IL-1 beta and IL-6 mRNA expression in hippocampal neurons in chronic inflammation model of aged rats. Acta Pharmacologica Sinica 2000;21:915-918.
17.Kim K, Kim HY: Korean red ginseng stimulates insulin release from isolated rat pancreatic islets. Journal of Ethnopharmacology 2008;120:190-195.
18.Poindexter BJ, Allison AW, Bick RJ, Dasgupta A: Ginseng: Cardiotonic in adult rat cardiomyocytes, cardiotoxic in neonatal rat cardiomyocytes. Life Sciences 2006;79:2337-2344.
19.林昭榮: 山藥的栽培與加工. 台灣農村 1992;20:23-25.
20.賴宏亮, 鄧秀玟, 劉新裕, 許博文: 山藥藥材鑑別之研究. 藥物食品分析 1999;7:313-325.
21.徐原田: 台灣農家要覽. 台灣, 豐年社, 1992.
22.周道成: 山藥的妙用食療法. 台灣, 安帆出版社, 2004.
23.Jau-Tien L, Deng-Jye Y: Determination of steroidal saponins in different organs of yam (Dioscorea pseudojaponica Yamamoto). Food Chemistry 2008;108:1068-1074.
24.Callaghan RM, A. VJ: Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiological Reviews 2006;86:245-278.
25.Zhang L, Liu Y, Chen G: Simultaneous determination of allantoin, choline and L-arginine in Rhizoma Dioscoreae by capillary electrophoresis. Journal of Chromatography, A 2004;1043:317-321.
26.Ravikumar PR, Hammesfahr P, Sih CJ: Cytotoxic saponins from the Chinese herbal drug Yunnan Bai Yao. Journal of Pharmaceutical Sciences 1979;68:900-903.
27.Sung MK, Kendall CW, Rao AV: Effect of soybean saponins and gypsophila saponin on morphology of colon carcinoma cells in culture. Food and Chemical Toxicology 1995;33:357-366.
28.Perry.L.M.: Medicinal Plants of East and South East Asia: Attributed Properties and Uses. Massachusetts, 1980.
29.Nair KS, Rizza RA, O''Brien P, Dhatariya K, Short KR, Nehra A, Vittone JL, Klee GG, Basu A, Basu R, Cobelli C, Toffolo G, Dalla Man C, Tindall DJ, Melton LJ, 3rd, Smith GE, Khosla S, Jensen MD: DHEA in elderly women and DHEA or testosterone in elderly men. The New England Journal of Medicine 2006;355:1647-1659.
30.Ni cc: Effect of various species Dioscorea spp. on hyperuricemia and kidney protection. Master Thesis, Institute of Nutritional Science, Chung Shan Medical University 2008.
31.Andraws R, Berger JS, Brown DL: Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. The Journal of the American Medical Association 2005;293:2641-2647.
32.Moncada S, Higgs A: The L-arginine-nitric oxide pathway. The New England Journal of Medicine 1993;329:2002-2012.
33.Radomski MW, Salas E: Nitric oxide--biological mediator, modulator and factor of injury: its role in the pathogenesis of atherosclerosis. Atherosclerosis 1995;118 Suppl:S69-80.
34.Cooke JP, Tsao PS: Arginine: a new therapy for atherosclerosis? Circulation 1997;95:311-312.
35.Lefer AM: Nitric oxide: nature''s naturally occurring leukocyte inhibitor. Circulation 1997;95:553-554.
36.Nava E, Noll G, Luscher TF: Nitric oxide in cardiovascular diseases. Annals of Medicine 1995;27:343-351.
37.Michel T, Feron O: Nitric oxide synthases: which, where, how, and why? The Journal of Clinical Investigation 1997;100:2146-2152.
38.Forstermann U, Schmidt HH, Pollock JS, Sheng H, Mitchell JA, Warner TD, Nakane M, Murad F: Isoforms of nitric oxide synthase. Characterization and purification from different cell types. Biochemical Pharmacology 1991;42:1849-1857.
39.Balligand JL, Cannon PJ: Nitric oxide synthases and cardiac muscle. Autocrine and paracrine influences. Arteriosclerosis, Thrombosis, and Vascular Biology 1997;17:1846-1858.
40.Schuman EM, Madison DV: Nitric oxide and synaptic function. Annual Review of Neuroscience 1994;17:153-183.
41.Gresser U, Gleiter CH: Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature. European Journal of Medical Research 2002;7:435-446.
42.Uzunov P, Weiss B: Separation of multiple molecular forms of cyclic adenosine-3'',5''-monophosphate phosphodiesterase in rat cerebellum by polyacrylamide gel electrophoresis. Biochimica et Biophysica Acta 1972;284:220-226.
43.Abrams D, Schulze-Neick I, Magee AG: Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000;84:e4.
44.Klingenberg M: Pigment of rat liver microsomes. Archives of Biochemistry and Biophysics 1958;75:376-386.
45.Gonzalez FJ, Korzekwa KR: Cytochromes P450 expression systems. Annual Review of Pharmacology and Toxicology 1995;35:369-390.
46.Capdevila JH, Falck JR, Harris RC: Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. Journal of Lipid Research 2000;41:163-181.
47.Nebert DW, Russell DW: Clinical importance of the cytochromes P450. Lancet 2002;360:1155-1162.
48.Yu LJ, Matias J, Scudiero DA, Hite KM, Monks A, Sausville EA, Waxman DJ: P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metabolism and Disposition 2001;29:304-312.
49.Nelson DR: Cytochrome P450 and the individuality of species. Archives of Biochemistry and Biophysics 1999;369:1-10.
50.Norlin M, Wikvall K: Enzymes in the conversion of cholesterol into bile acids. Current Molecular Medicine 2007;7:199-218.
51.Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996;6:1-42.
52.Oesch-Bartlomowicz B, Richter B, Becker R, Vogel S, Padma PR, Hengstler JG, Oesch F: cAMP-dependent phosphorylation of CYP2B1 as a functional switch for cyclophosphamide activation and its hormonal control in vitro and in vivo. International Journal of Cancer 2001;94:733-742.
53.Ito S, Chen C, Satoh J, Yim S, Gonzalez FJ: Dietary phytochemicals regulate whole-body CYP1A1 expression through an arylhydrocarbon receptor nuclear translocator-dependent system in gut. The Journal of Clinical Investigation 2007;117:1940-1950.
54.Kishimoto R, Ueda M, Yoshinaga H, Goda K, Park SS: Combined effects of ethanol and garlic on hepatic ethanol metabolism in mice. Journal of Nutritional Science and Vitaminology 1999;45:275-286.
55.Takahashi M, Tsuboyama-Kasaoka N, Nakatani T, Ishii M, Tsutsumi S, Aburatani H, Ezaki O: Fish oil feeding alters liver gene expressions to defend against PPARalpha activation and ROS production. American Journal of Physiology - Gastrointestinal and Liver Physiology 2002;282:G338-348.
56.Garg R, Gupta S, Maru GB: Dietary curcumin modulates transcriptional regulators of phase I and phase II enzymes in benzo[a]pyrene-treated mice: mechanism of its anti-initiating action. Carcinogenesis 2008;29:1022-1032.
57.Woodcroft KJ, Novak RF: Insulin effects on CYP2E1, 2B, 3A, and 4A expression in primary cultured rat hepatocytes. Chemico-Biological Interactions 1997;107:75-91.
58.Zangar RC, Novak RF: Effects of fatty acids and ketone bodies on cytochromes P450 2B, 4A, and 2E1 expression in primary cultured rat hepatocytes. Archives of Biochemistry and Biophysics 1997;337:217-224.
59.Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-491.
60.Yamashita T, Hashimoto S, Kaneko S, Nagai S, Toyoda N, Suzuki T, Kobayashi K, Matsushima K: Comprehensive gene expression profile of a normal human liver. Biochemical and Biophysical Research Communications 2000;269:110-116.
61.Gallagher EP, Kunze KL, Stapleton PL, Eaton DL: The Kinetics of Aflatoxin B1Oxidation by Human cDNA-Expressed and Human Liver Microsomal Cytochromes P450 1A2 and 3A4. Toxicology and Applied Pharmacology 1996;141:595-606.
62.Usui T, Saitoh Y, Komada F: Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biological & Pharmaceutical Bulletin 2003;26:510-517.
63.Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM, Zetterstrom RH, Perlmann T, Lehmann JM: An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998;92:73-82.
64.Yanagimoto T, Itoh S, Sawada M, Kamataki T: Mouse cytochrome P450 (Cyp3a11): predominant expression in liver and capacity to activate aflatoxin B1. Archives of Biochemistry and Biophysics 1997;340:215-218.
65.Yanagimoto T, Itoh S, Sawada M, Hashimoto H, Kamataki T: Molecular cloning and functional expression of a mouse cytochrome P-450 (Cyp3a-13): examination of Cyp3a-13 enzyme to activate aflatoxin B1 (AFB1). Biochimica et Biophysica Acta 1994;1201:405-410.
66.Yanagimoto T, Itoh S, Muller-Enoch D, Kamataki T: Mouse liver cytochrome P-450 (P-450IIIAM1): its cDNA cloning and inducibility by dexamethasone. Biochimica et Biophysica Acta 1992;1130:329-332.
67.Itoh S, Satoh M, Abe Y, Hashimoto H, Yanagimoto T, Kamataki T: A novel form of mouse cytochrome P450 3A (Cyp3a-16). Its cDNA cloning and expression in fetal liver. European Journal of Biochemistry 1994;226:877-882.
68.Wang MY, Liehr JG: Lipid hydroperoxide-induced endogenous DNA adducts in hamsters: possible mechanism of lipid hydroperoxide-mediated carcinogenesis. Archives of Biochemistry and Biophysics 1995;316:38-46.
69.Draper HH, Agarwal S, Nelson DE, Wee JJ, Ghoshal AK, Farber E: Effects of peroxidative stress and age on the concentration of a deoxyguanosine-malondialdehyde adduct in rat DNA. Lipids 1995;30:959-961.
70.Mahmoodi H, Hadley M, Chang YX, Draper HH: Increased formation and degradation of malondialdehyde-modified proteins under conditions of peroxidative stress. Lipids 1995;30:963-966.
71.Janero DR: Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radical Biology & Medicine 1990;9:515-540.
72.Cotgreave IA, Moldeus P, Orrenius S: Host biochemical defense mechanisms against prooxidants. Annual Review of Pharmacology and Toxicology 1988;28:189-212.
73.Seeger W, Roka L, U M: Detection of organic hydroperoxides in rabbit lung lavage fluid, but not in lung tissue homogenate, using GSH peroxidase and GSH reductase. Journal of Clinical Chemistry & Clinical Biochemistry 1984;22:711-715.
74.Jenkinson SG, Lawrence RA, Tucker WY: Glutathione peroxidase, superoxide dismutase, and glutathione S-transferase activities in human lung. American Review Of Respiratory Disease 1984;130:302-304.
75.Kosower NS, Kosower EM: Formation of disulfides with diamide. Methods in Enzymology 1987;143:264-270.
76.Ursini F, Maiorino M, Brigelius-Flohe R, Aumann KD, Roveri A, Schomburg D, Flohe L: Diversity of glutathione peroxidases. Methods in Enzymology 1995;252:38-53.
77.Lu SC: Regulation of hepatic glutathione synthesis: current concepts and controversies. Federation of American Societies for Experimental Biology Journal 1999;13:1169-1183.
78.Fink MP, Payen D: The role of nitric oxide in sepsis and ARDS: synopsis of a roundtable conference held in Brussels on 18-20 March 1995. Journal of Intensive Care Medicine 1996;22:158-165.
79.Zhang H, Pakeerappa P, Lee HJ, Fisher SA: Induction of PDE5 and de-sensitization to endogenous NO signaling in a systemic resistance artery under altered blood flow. Journal of Molecular and Cellular Cardiology 2009;47:57-65.
80.Bentlin MR, Saito A, De Luca AK, Bossolan G, Bonatto RC, Martins AS, Rugolo LM: Sildenafil for pulmonary hypertension treatment after cardiac surgery. Journal of Pediatrics 2005;81:175-178.
81.Martina V, Masha A, Gigliardi VR, Brocato L, Manzato E, Berchio A, Massarenti P, Settanni F, Della Casa L, Bergamini S, Iannone A: Long-term N-acetylcysteine and L-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. Diabetes Care 2008;31:940-944.
82.Moubarak AS, Rosenkrans CF: Hepatic Metabolism of Ergot Alkaloids in Beef Cattle by Cytochrome P450. Biochemical and Biophysical Research Communications 2000;274:746-749.
83.Barakat M, El-Kadi AOS, Souich PD: In Vivo, Ex Vivo, and In Vitro Effects of L-NAME and L-arginine on the Metabolism of the Ophylline in the Rabbit. Drug Metabolism and Disposition 1996;25:191-195.
84.Janetzky K, Morreale AP: Probable interaction between warfarine and ginseng. American Journal of Health-System Pharmacy 1997;54:692-693.
85.Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY: Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clinical Pharmacology & Therapeutics 2002;72:276-287.
86.McCord JM, Fridovich I: Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). Journal of Biological Chemistry 1969;244:6049-6055.
87.Kehrer JP: Free radicals as mediators of tissue injury and disease. Critical Reviews in Toxicology 1993;23:21-48.
88.Sies H: Glutathione and its role in cellular functions. Free Radical Biology & Medicine 1999;27:916-921.
89.Dringen R: Metabolism and functions of glutathione in brain. Progress in Neurobiology 2000;62:649-671.




QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top